Now recruiting 2 job positions: Senior Molecular Diagnostics Scientist NGS + Molecular Diagnostics Scientist dPCR

Now recruiting 2 job positions: Senior Molecular Diagnostics Scientist NGS + Molecular Diagnostics Scientist dPCR

POSITION 1: Senior Molecular Diagnostics Scientist, NGS SAGA Diagnostics AB is seeking a talented and highly motivated NGS scientist with strong interest in advancing our mission to revolutionize cancer diagnostics through proprietary ultrasensitive technologies that measure circulating tumor DNA in minimally-invasive “liquid biopsies” such as a simple blood sample.   The candidate will work in a […]

SAGA expands with four new team members to further accelerate commercial and medical development

SAGA expands with four new team members to further accelerate commercial and medical development

LUND, Sweden — /November 7, 2019/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announces the appointment of four people to significantly strengthen SAGA’s team: Annina Hube, PhD MBA, as Director of Market Access, Rocco Crescenzo, MD as Chief Medical Officer,  and Maria Fe Paz, MD […]

SAGA lands agreement with Region Örebro University Hospital to deploy ultra sensitive liquid biopsy testing in lung cancer

SAGA lands agreement with Region Örebro University Hospital to deploy ultra sensitive liquid biopsy testing in lung cancer

LUND, Sweden — /September 9, 2019/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announces it has entered a “lab-in-lab” customer agreement with the University Hospital Örebro (USÖ), Division of Laboratory Medicine, serving the healthcare region of Örebro County. […]

Appointment of Director of Operations

Appointment of Director of Operations

LUND, Sweden — /September 2, 2019/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announces the appointment of a new Director of Operations, Johanna Asklin, PhD, an experienced professional project and portfolio manager in the life sciences.  “We are pleased […]

SAGA raises 40 million SEK (€3.7 million) to advance ultrasensitive cancer liquid biopsies

SAGA raises 40 million SEK (€3.7 million) to advance ultrasensitive cancer liquid biopsies

LUND, Sweden and OSLO, Norway, June 11, 2019 — /B3C Newswire/ — SAGA Diagnostics AB, a precision oncology genomics testing company focused on ultrasensitive monitoring of cancer patients using blood samples and other liquid biopsies and tissues, today announces the raising of SEK 40 million in venture-backed financing (circa EUR 3.7 million, USD 4.2 million).  Hadean […]

SAGA appoints new Director of Finance

SAGA appoints new Director of Finance

LUND, Sweden — /February 11, 2019/ — SAGA Diagnostics AB, a genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients using a simple blood sample, today announces the appointment of a new Director of Finance, Henrik Simonsen, a veteran strategic CFO with over 20 years of executive and corporate finance […]

Job opening: Medical Laboratory Scientist in molecular cancer diagnostics

Job opening: Medical Laboratory Scientist in molecular cancer diagnostics

Now hiring:  [*** POSITION FILLED ***] Medical Laboratory Scientist I/II in Lund, Sweden SAGA Diagnostics AB is seeking a team-oriented Medical Laboratory Scientist (laboratory technician) to join us in our mission to revolutionize cancer diagnostics through proprietary ultrasensitive technologies to measure circulating tumor DNA in minimally-invasive “liquid biopsies” such as a simple blood sample.  Make a […]

SAGA awarded €450,000 grant from Sweden’s SWElife Innovation Program

SAGA awarded €450,000 grant from Sweden’s SWElife Innovation Program

LUND, Sweden — /November 15, 2018/ — SAGA Diagnostics announced today it has been awarded a follow-on grant of SEK 4.7 million (~ €450,000) from the SWElife Accelerator Innovation Program to support the product development objectives of SAGA’s ultrasensitive technologies for monitoring cancer patients using simple blood samples and other “liquid biopsies”. The grant will […]

WntResearch selects SAGA’s ctDNA monitoring tool KROMA for phase 2 clinical trial

WntResearch selects SAGA’s ctDNA monitoring tool KROMA for phase 2 clinical trial

LUND, Sweden — /August 30, 2018/ — SAGA Diagnostics AB, a genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients using a simple blood sample, today announces it has entered a customer agreement with WntResearch AB, a Swedish biopharma company advancing new anti-cancer therapies targeting the Wnt5A pathway.  WntResearch is […]

SAGA inks deal with Center for Molecular Diagnostics for lung cancer and leukemia tests

SAGA inks deal with Center for Molecular Diagnostics for lung cancer and leukemia tests

LUND, Sweden — /June 14, 2018/ — SAGA Diagnostics AB, a genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients using a simple blood sample, today announces it has entered a customer agreement with the Center for Molecular Diagnostics, Region Skåne, part of the Skåne University Hospital system serving the […]